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HomosycteineBackground: Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme involved in folate/homocys-
teine metabolism. A polymorphism C677T has been reported to be linked with risk of several diseases/
disorders like birth defects, metabolic and psychiatric disorders and different cancers. The association
between esophageal cancer and MTHFR gene C677T polymorphism has been investigated in several
case-control studies, which rendered contradictory results.
Aim: To shed light on association between MTHFR C677T polymorphism and risk of esophageal cancer, a
meta-analysis of published case control association studies was conducted.
Methods: Four electronic databases: PubMed, Google Scholars, Elsevier and Springer Link were searched
up to August 2016. All statistical analyses were performed using MetaAnalyst and Mix (version 1.7). Odds
ratios (ORs) with their 95% confidence intervals (95% CIs) were calculated. Total twenty-nine studies with
6520 cases and 9192 controls were included in the present meta-analysis.
Results: The results of meta-analysis suggested that there were significant association between C677T
polymorphism and esophageal cancer risk using overall comparisons in five genetic models (T vs. C:
OR = 1.20, 95% CI = 1.1–1.27, p = <0.0001; TT + CT vs. CC: OR = 1.37, 95% CI = 1.14–1.62, p = 0.0004; TT
vs. CC: OR = 1.43, 95% CI = 1.1–1.84, p = 0.005; CT vs. CC OR = 1.35, 95% CI = 1.15–1.58, p = 0.0002; TT
vs. CT + CC: OR = 1.19, 95% CI = 0.99–1.42, p = 0.05). Publication bias was absent. Subgroup analysis based
on ethnicity and source of controls were also performed.
Conclusion: In conclusion, results of present meta-analysis showed significant association between
MTHFR C677T polymorphism and esophageal cancer.
 2018 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
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Fig. 1. Flow diagram of study search and selection process.1. Introduction
Esophageal cancer is the sixth most common cancer worldwide,
which is characterized by rapid development [1–3] and survival
rates for esophageal cancer are quiet poor [4,5]. Its incidence rates
vary globally, and the highest rates found in Southern and Eastern
Africa and Eastern Asia [3]. Higher incidence of the cancer in cer-
tain geographic regions suggests the role of environmental risk fac-
tors such as nutritional deficiency, in its pathogenesis [6–9].
Folate deficiency resulting from low consumption of vegetables
and fruits is associated with increased risk of esophageal cancer
[9]. The biological function of folate is to provide methyl groups,
required for DNA methylation and synthesis [10]. Therefore, folate
deficiency is thought to be carcinogenic through disruption of DNA
methylation, synthesis, and impaired repair. Besides inadequate
folate intake, functional polymorphisms in folate metabolizing
genes especilaly methylenetetrahydrofolate reductase (MTHFR)
C677T polymorphism may also influence susceptibility to cancer.
MTHFR is a key enzyme of folate metabolism. It catalyzes irre-
versible reduction of 5, 10-methylene tetrahydrofolate to 5-methyl
tetra-hydro folate, which provides the methyl group with the abil-
ity to convert homocysteine to methionine, the precursor of
S-adenosyl methionine (SAM). SAM is a universal methyl-group
donor for methylation of a wide variety of biological substrates.
MTHFR is also involved in production of deoxythymidine
monophosphate (dTMP) via thymidylate synthase and purine syn-
thesis. Therefore, MTHFR is also thought to play a role in the pro-
vision of nucleotides essential for DNA synthesis and repair [11].
MTHFR gene is located at 1p36.3 [12] and Frosst et al. [11] iden-
tified a single nucleotide polymorphism (SNP), the C to T transition
at nucleotide 677 in exon 4 of the MTHFR gene (rs1801133), which
results in an alanine (A) to valine (V) substitution (A222V). Individ-
uals with homozygous variant 677TT and heterozygote 677CT
genotypes have only about 30% and 65%, respectively, of in vitro
enzyme activity as compared to those with 677CC wild type geno-
type [11]. The frequency of C677T polymorphism varies greatly in
different populations [13–15].
Epidemiologic studies have revealed that MTHFR C677T poly-
morphism is associated with an increased risk of endometrial can-
cer [16], cervical intraepithelial neoplasia [17], breast cancer [18],
gastric cancer [19] and bladder cancer [20] etc. Several case control
studies [21–28] were investigated MTHFR gene C677T polymor-
phism as risk for esophageal cancer but results were contradictory.
Hence, we performed a meta-analysis of case-control studies, to
obtain a more precise estimation of the relationship between
MTHFR C677T polymorphism and esophageal cancer risk.
2. Methods
Meta-analysis was carried out according to MOOSE guidelines
[29].
2.1. Search strategy and identification of studies
A literature search of the PubMed (http://www.ncbi.nlm.nih.-
gov/pubmed), Google Scholar (http://scholar.google.com), Science
Direct (http://www.sciencedirect.com), and Springer Link (http://
link.springer.com) databases (updated to August 2016) was con-ducted using combinations of the following terms: ‘‘polymorphism
or variant or mutation” and ‘‘Esophageal cancer” and
‘‘Methylenetetrahydrofolate reductase or MTHFR”.
2.2. Inclusion/exclusion criteria of studies
Studies that were included in the present meta-analysis had to
meet the following criteria: (1) study should evaluate MTHFR gene
C677T polymorphism in esophageal cancer cases, (2) study should
be a case-control, and (3) study should report sufficient genotype/
allele numbers for estimation of odds ratio (OR) with a 95% confi-
dence interval (CI). Accordingly, the following exclusion criteria
were also used: (1) editorials, abstracts, reviews and linkage or
pedigree studies, (2) only cases were reported, and (3) studies that
did not report genotype/allele number.
2.3. Data extraction
The following information was extracted from each included
study: first author’s family name, journal name, year of publica-
tion, country name and number of cases and controls. Number of
alleles or genotypes in both cases and controls were extracted or
calculated from published data to recalculate ORs.
2.4. Statistical analysis
Crude odds ratio with 95% CI were used to assess strength of
association between MTHFR C677T genotypes and risk of esopha-
geal cancer in log additive/ allele contrast (T vs C), homozygote
(TT vs CC), co-dominant/heterozygote (CT vs CC), dominant
(TT + CT vs CC) and recessive (TT vs CT + CC) models. The statistical
significance of the pooled OR was determined using a Z test, and
p < 0.05 was considered statistically significant.
Table 1
Distribution of different genotypes in included thirty-two studies.
Study Country Case/Control Case genotype Control Genotype HWE P- value
CC CT TT CC CT TT
Song et al. (2001) China 240/360 29 118 93 126 172 62 0.82
Miao et al. (2002) China 217/468 47 107 63 151 217 100 0.18
Wu et al. (2002) China 93/200 31 47 15 63 99 38 0.93
Stolzenberg et al. (2003) China 129/398 23 58 48 65 209 124 0.14
Zhang et al. (2003) China 198/141 16 93 89 25 54 62 0.05
Kureshi et al. (2004) Pakistan 34/54 22 12 0 32 18 4 0.51
Zhang et al. (2004), China China 189/141 16 93 80 25 54 62 0.03*
Zhang et al. (2004), Germany Germany 241/256 94 116 31 107 115 34 0.74
Wang et al. (2005) China 275/315 51 105 119 74 143 98 0.12
Yang et al. (2005) China 165/493 63 82 20 186 227 80 0.44
Feng et al. (2006) China 275/315 51 105 119 74 143 98 0.12
Zhang et al. (2006), Kazakh China 94/98 53 34 7 57 29 12 0.01*
Zhang et al. (2006), Han China 84/57 27 34 23 13 30 14 0.68
He et al. (2007) China 584/540 73 263 248 119 234 187 0.005*
Li et al. (2008) China 126/169 22 52 52 41 62 66 0.001*
Qin et al. (2008) China 120/240 60 53 7 170 59 11 0.06
Chen et al. (2009) China 103/181 11 49 43 45 85 51 0.42
Langevin et al. (2009) Mixed 725/1531 209 328 188 486 731 314 0.19
Wang et al. (2009) China 102/110 39 47 16 58 36 16 0.01*
Umar et al. (2010) India 208/223 155 48 5 155 63 5 0.63
Cai et al. (2011) China 125/250 32 66 27 114 95 41 0.007*
Li et al. (2011) China 270/262 112 113 45 95 82 85 000*
Zhao et al. (2011) China 155/310 68 74 13 179 120 11 0.09
Ekiz et al. (2012) Turkey 26/30 17 9 0 16 12 2 0.9
Jing et al.,2012 China 168/92 75 74 19 37 41 14 0.05
Yang et al. (2012) China 100/97 37 45 18 40 41 16 0.32
Huang et al. (2013), EPL China 109/167 52 37 20 90 60 17 0.14
Hunag et al. (2013), ESCC China 126/167 44 65 17 90 60 17 0.14
Qu et al. (2013) China 378/425 69 181 128 47 185 193 0.78
Chang et al. (2014) USA 202/391 65 105 32 135 199 57 0.23
Keld et al. (2014) UK 44/58 19 20 5 27 27 4 0.42
Tang et al. (2014) China 615/653 188 288 139 188 348 117 0.06
* Control population of these studies was not in Hardy Weinberg Equilibrium.
Table 2
Summary estimates for the odds ratio (OR) of MTHFR C677T in various allele/genotype contrasts, the significance level (p value) of heterogeneity test (Q test), and the I2 metric
and publication bias p-value (Egger Test).
Genetic models Fixed effect OR (95% CI), p Random effect OR (95% CI), p Heterogeneity p-value (Q test) I2 (%) Publication bias
(p of egger’s test)
All studies (32)
Allele Contrast (T vs C) 1.19(1.13–1.24), <0.0001 1.19(1.05–1.32),0.003 <0.0001 79.66 0.82
Co-dominant (Ct vs CC) 1.23(1.13–1.33),<0.0001 1.29(1.11–1.49),0.0007 <0.0001 67.52 0.18
Homozygote (TT vs CC) 1.38(1.25–1.52),<0.0001 1.38(1.10–1.72),0.004 <0.0001 76.69 0.80
Dominant (TT + CT vs CC) 1.27(1.18–1.36),<0.0001 1.3(1.12–1.53),0.0007 <0.0001 74.62 0.39
Recessive (TT vs CT + CC) 1.21(1.12–1.31),<0.0001 1.18(1.0–1.38),0.04 <0.0001 70.65 0.37
Asian studies (28)
Allele Contrast (T vs C) 1.2(1.13–1.26),<0.0001 1.2(1.04–1.35),0.01 <0.0001 82.1 0.76
Co-dominant (Ct vs CC) 1.28(1.17–1.40), <0.0001 1.33(1.11–1.58),0.001 <0.0001 70.57 0.34
Homozygote (TT vs CC) 1.40(1.25–1.56), <0.0001 1.38(1.07–1.82),0.01 <0.0001 79.44 0.75
Dominant (TT + CT vs CC) 1.31(1.2–1.42), <0.0001 1.34(1.11–1.61),0.002 <0.0001 77.47 0.52
Recessive (TT vs CT + CC) 1.2(1.10–1.30), <0.0001 1.17(0.97–1.66), 0.0.09 <0.0001 73.88 0.45
Caucasian studies (4)
Allele Contrast (T vs C) 1.14(1.03–1.23), 0.009 1.14(1.03–1.26), 0.009 0.82 0 0.49
Co-dominant (Ct vs CC) 1.07(0.91–1.25),0.4 1.07(0.91–1.25),0.4 0.97 0 0.5
Homozygote (TT vs CC) 1.31(1.07–1.60),0.009 1.31(1.07–1.60),0.009 0.73 0 0.68
Dominant (TT + CT vs CC) 1.14(0.98–1.320),0.09 1.14(0.98–1.320),0.09 0.96 0 0.49
Recessive (TT vs CT + CC) 1.27(1.06–1.51),0.007 1.27(1.06–1.51),0.007 0.57 0 0.6
Hospital based controls (17)
Allele Contrast (T vs C) 1.12(1.03–1.20),0.003 1.15(0.98–1.35),0.08 <0.0001 75.43 0.58
Co-dominant (Ct vs CC) 1.2(1.07–1.35),0.001 1.27(1.02–1.57),0.02 <0.0001 67.96 0.35
Homozygote (TT vs CC) 1.15(0.98–1.35),0.07 1.26(0.98–1.71),0.14 <0.0001 66.76 0.77
Dominant (TT + CT vs CC) 1.19(1.07–1.32),0.001 1.25(1.01–1.55),0.03 <0.0001 71.27 0.36
Recessive (TT vs CT + CC) 1.08(0.94–1.24),0.27 1.11(0.85–1.44),0.43 0.0004 61.98 0.99
Population based studies (16)
Allele Contrast (T vs C) 1.22(1.15–1.29),<0.0001 1.21(1.03–1.39),0.01 <0.0001 82.36 0.71
Co-dominant (Ct vs CC) 1.24(1.11–1.37),<0.0001 1.29(1.05–1.57),0.01 <0.0001 67.22 0.33
Homozygote (TT vs CC) 1.51(1.34–1.70),<0.0001 1.48(1.10–2.00),0.009 <0.0001 80.95 0.74
Dominant (TT + CT vs CC) 1.33(1.20–1.46),<0.0001 1.35(1.08–1.68),0.007 <0.0001 76.65 0.61
Recessive (TT vs CT + CC) 1.27(1.15–1.39),<0.0001 1.26(1.01–1.51),0.03 <0.0001 75.27 0.43
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Fig. 2. Random effect forest plot of allele contrast model (T vs. C) of MTHFR C677T polymorphism.
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Fig. 3. Random effect forest plot of homozygote model (TT vs. CC) of MTHFR C677T polymorphism.
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Fig. 4. Random effect forest plot of allele contrast model (T vs. C) of Asian studies.
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and was considered statistically significant when p < 0.05 [30]. The
pooled OR was estimated using the fixed effects model when there
was less heterogeneity [31] or random effects model when there
was higher heterogeneity [32]. All included studies were tested
for genotypic distribution of the MTHFR C677T polymorphism in
the control group with the HWE principle using the x2-test, and
considered p < 0.05 as statistically significant. Sensitivity analysis
was carried out by excluding studies not in HWE [33]. Subgroup
analysis was also performed on the basis of ethnicity of subjects
and source of controls.2.5. Publication bias
Funnel plots were used to detect publication bias. However, due
to the limitations of funnel plotting, which require a range of stud-
ies of varying sizes involving subjective judgments, publication
bias was evaluated using Egger’s linear regression test [34], which
measures funnel plot asymmetry using a natural logarithm scale of
OR. Begg’s correlation test also was performed [35]. All p-values
are two tailed with a significance level at 0.05. All statistical anal-
yses were undertaken by MetaAnalyst [36] and MIX version 1.7
[37].
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3.1. Characteristics of included studies
Eighty-six studies were retrieved by literature search strategy.
Out of these, 29 articles were excluded. The excluded papers
included book chapters, reviews, letter to editor and irrelevant arti-
cles. After reviewing the abstract and papers of remaining 57 arti-
cles, 19 articles were also excluded (11 articles were duplicates and
8 articles were not case control). Further nine studies were
excluded from the analysis as they were meta-analyses (Fig. 1).
Only 29 articles, qualifying our strict selection criteria, were
included in the present meta-analysis [5,21–28,38–57]. Out of 29
studies, 23 studies were carried out on Chinese subjects and
remaining studies were carried out in six other countries- Pakistan
[22], Germany [42], India [23], Turkey [5], Britain [28], America
[56]. Three authors [42,46,55] studied two different population
samples, in present meta-analysis we considered each population
as individual study/sample. So finally we have thirty-two studies
to include in the present meta-analysis. Number of cases, controls
and different genotypes data for all these thirty-two studies were
tabulated (Table 1).
Overall, thirty-two studies provided 6,520/9192 cases/controls
for MTHFR C677T polymorphism. The percentage frequency of TT
genotype among cases and controls was 26.52% and 22%, respec-
tively whereas prevalence of CT heterozygotes among cases was
44.8% and 44.1% in controls. The prevalence of CC homozygote
among patients and controls was 28.7% and 34.05%, respectively.Fig. 5. Random effect forest plot of allele contThe prevalence of T allele was 48.9% and 43.9% for the case and
control groups, respectively. In all the studies except seven
[24,25,42,46–48,52] the distribution of genotypes in the control
group was in Hardy Weinberg equilibrium.3.2. Meta-analysis
A summary of meta-analyses findings regarding associations
between the MTHFR C677T polymorphism and esophageal cancer
is given in Table 2. Meta-analysis revealed a significant association
between esophageal cancer and MTHFR T allele (T vs C) with both
fixed effects (OR = 1.19, 95% CI = 1.13–1.24, p < 0.0001) and ran-
dom effects model (OR = 1.18, 95% CI = 1.05–1.32, p = 0.003)
(Fig. 2; Table 2). Results showed an increased risk of oesophageal
cancer among mutant homozygote variants (TT vs. CC; homozy-
gote model), with both fixed (OR = 1.38; 95%CI = 1.25–1.523; p=
<0.001) and random (OR = 1.38; 95%CI = 1.10–1.72; p = 0.004)
effect models (Fig. 3; Table 2).
Combined mutant genotypes (TT + CT vs. CC; dominant model)
showed positive significant association with oesophageal cancer
using both fixed (OR = 1.27; 95%CI = 1.18–1.36; p = <0.0001) and
random (OR = 1.3; 95%CI = 1.12–1.53; p = 0.0007) effect models
(Table 2). Similarly the recessive genotypes model (TT vs. CT +
CC) also showed significant association with oesophageal cancer
with both fixed (OR = 1.21; 95%CI = 1.12–1.31; p = <0.0001) and
random (OR = 1.18; 95%CI = 1.0–1.38; p = 0.04) effect models
(Table 2).rast model (T vs. C) of Caucasian studies.
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We also performed sub-group analysis based on ethnicity and
source of controls. Out of 32 studies, 28 studies were from Asia
and 4 studies were from Caucasian population. In Asian popula-
tion (number of studies = 28; 5,308/6956 cases/controls), allele
contrast meta-analysis showed significant association adopting
both fixed (allele contrast: OR = 1.2; 95% CI = 1.13–1.26; p = <0.0
001) and random (OR = 1.2; 95% CI = 1.04–1.35; p = 0.01) effect
models. Combined mutant genotypes also showed significant
association with fixed (dominant model: OR = 1.31; 95% CI = 1.2
0–1.4; p < 0.0001) and random (OR = 1.34; 95% CI = 1.11–1.61; p
= 0.002) effect models (Fig. 4; Table 2). Results of Caucasian stud-
ies (number of studies = 16; 2916/4300 cases/controls) meta-
analysis also indicated significant association with both fixed
and random effects model (allele contrast: OR = 1.14; 95% CI = 1.
03–1.23; p = 0.009). The combined mutant genotype did not show
significant association with fixed and random effect models (dom-
inant model: OR = 1.14; 95% CI = 0.98–1.32; p = 0.09) (Table 2;
Fig. 5).
Subgroup analysis based on source of controls was also done.
Out of 32 studies, in 17 studies, controls were selected from hospi-
tal and in 16 studies controls were selected from the population.
Allele contrast meta-analysis of hospital based group, showed sig-
nificant association adopting fixed effects model (OR = 1.12; 95%
CI = 1.03–1.20; p = 0.003) but random effects model did not show
significant association (OR = 1.15; 95% CI = 0.98–1.35; p = 0.08)
(Table 2; Fig. 6). In population based group, allele contrast meta-Fig. 6. Random effect forest plot of allele contrast model (T vsanalysis showed significant association with both fixed (OR = 1.2;
95% CI = 1.15–1.29; p < 0.0001) and random (OR = 1.2; 95% CI = 1.
03–1.39; p = 0.01) effects models (Table 2; Fig. 7).3.4. Heterogeneity and sensitive analysis
A true heterogeneity existed for allele (Phetero = <0.0001, Q =
152.43, df = 33, I2 = 79.66%, t2 = 0.07), homozygote (Phetero = <0.00
01, Q = 132.973, df = 33, I2 = 76.69%, t2 = 0.27), heterozygote (Phetero
= <0.0001, Q = 95.54, df = 33, I2 = 67.52%, t2 = 0.11), mutant geno-
types (Phetero = <0.0001, Q = 122.15, df = 33, I2 = 74.62%, t2 = 0.14)
and recessive (Phetero = <0.0001, Q = 105.62, df = 33, I2 = 70.65%, t2
= 0.13) comparisons. The ‘I20 value of more than 50% in both allele
and genotype analysis shows high level of true heterogeneity.
In allele contrast meta-analysis, sensitivity analysis performed
by exclusion of the studies in which control population was not
in Hardy Weinberg equilibrium and studies with small sample size
(n h1 0 0). Control population of seven studies [24,25,42,46–48,52],
were not in HW equilibrium and heterogeneity did not decrease
after exclusion of these studies (p = <0.0001, I2 = 79.55%). Exclusion
of six studies involving small sample size, <100 (Wu et al. [39], n =
93; Kureshi et al. [22], n = 34; Zhang et al. [46] (Kazakh), n = 94;
Zhang et al. [46] (Han), n = 84; Ekiz et al. [5], n = 26; Keld et al.,
[28], n = 44), heterogeneity did not decrease (P < 0.0001, I2 =
82.55%), but odds ratio was increased (OR = 1.23; 95%CI = 1.14–1.
26;p < 0.0001).. C) of studies included hospital based control population.
Fig. 7. Random effect forest plot of allele contrast model (T vs. C) of studies included population based control population.
Fig. 8. Funnel plots of precision by OR of MTHFR C677T allele contrast model (T vs. C).
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Fig. 9. Funnel plots of standard error by OR of MTHFR C677T allele contrast model (T vs. C).
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Funnel plots, Begg’s and Egger’s test were performed to esti-
mate the risk of publication bias. The shape of funnel plots in all
contrast models were symmetrical (Table 2; Figs. 8 and 9). In addi-
tion, the P values of Egger’s test were more than 0.05, which pro-
vided statistical evidence for the symmetry of funnel plots in the
meta-analysis (p = 0.82 for T vs. C; p = 0.80 for TT vs CC; and p =
0.18 for CT vs. CC; p = 0.39 for TT + CT vs. CC; p = 0.37 for TT vs.
CT + CC) (Table 2). Begg’s test results also did not show publication
bias (p = 0.44 for T vs. C; p = 0.41 for TT vs CC; and p = 0.91 for CT
vs. CC; p = 0.44 for TT + CT vs. CC; p = 0.09 for TT vs. CT + CC).4. Discussion
Meta-analysis of thirty-two case control association studies
revealed that there was a modest significant association between
MTHFR C677T polymorphism and susceptibility of esophageal can-
cer. It was reported very well that folate deficiency and MTHFR
C677T polymorphism increased the risk of different types of cancer
[10,16–20,58,59]. MTHFR polymorphisms have been shown to
modulate risk of cancer with the association being that MTHFR iso-
forms increase homocysteine levels, which consequently increase
the cancer risk [60] by increasing DNA damage and mutations in
tumor suppressor genes.
Folate functions as methyl donor in the one carbon metabolism
pathway, an essential process in DNA synthesis, repair and methy-
lation and dysregulation of the folate metabolic pathway either
due to deficiency of folate or MTHFR C677T polymorphism could
result in carcinogenesis [10,61]. There are two important mecha-
nisms by which folate deficiency may influence the risk of cancer:
(i) by inducing misincorporation of uracil into DNA, which can lead
to chromosomal breaks and mutations [60,62,63], and/or (ii) by
causing aberrant DNA methylation, resulting in altered expression
of critical proto-oncogenes and tumor suppressor genes.Meta-analysis is a powerful tool for summarizing the different
studies. It can not only overcome the problem of small size and
inadequate statistical power of genetic studies of complex traits
but also provide more reliable results than a single case-control
study. Several meta-analysis were published which investigated
the association between folate pathway genes polymorphisms
and different disease/disorders like- down syndrome [64–66], cleft
lip and palate [67,68], recurrent pregnancy loss [69], male infertil-
ity [70], neurodegenerative disorders [71], psychiatric disorders
[72–75], and different cancers [76–80].
Seven meta-analyses [51,81–86] examined the effect of MTHFR
C677T polymorphism on esophageal cancer risk, but no consistent
conclusion was achieved. The discrepancy of results may be due
to the difference in ethnic background and environmental exposure
as well as dietary intake of folate, smoking status and use of alcohol.
In interpretation of results of present meta-analysis, some lim-
itations should be considered like- (i) crude OR was used, (ii)
higher heterogeneity was present, (iii) only four databases were
searched for articles, (iv) single gene polymorphism was consid-
ered, (vi) all case control studies were from Asian and Caucasian
populations, African studies were not included and (vii) gene-
gene and gene-environment interactions were not considered.
In conclusion, present meta-analysis supports the hypothesis
that MTHFR C677T polymorphism may play a role in the etiology
of esophageal cancer. Large studies that assess the interrelations
between folate intake, MTHFR polymorphism, alcohol intake and
smoking are needed to further clarify the role of MTHFR polymor-
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